Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107, United States
NCT Number: NCT07608276
The objective of this study is to evaluate the clinical impact of the NOL nociception level index monitoring on intraoperative and post operative patient outcomes and institutional metrics when used to guide intraoperative analgesia dosing in patients undergoing spine surgery under general anesthesia when compared to a case controlled retrospective cohort.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Philadelphia, Pennsylvania, 19107, United States
The study will assess the impact of intraoperative use of NOL nociception monitoring in in-hospital spine surgery procedures performed under general anesthesia on post operative patient outcomes. The study is designed as a quality improvement project with the prospective outcomes to be compared to a retrospective matched cohort. The objective of this study is to evaluate the clinical impact of the device on intraoperative and post operative patient outcomes and institutional metrics when used to guide intraoperative analgesia dosing in patients undergoing spine surgery under general anesthesia when compared to a case controlled retrospective cohort. The clinical impact will also be translated into economic metrics.
Secondary endpoints
INTRAOPERATIVE
WARD - up to 48 hours post surgery
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The PMD-200 monitor with the NOL index will be used to guide analgesia dosing during anesthesia maintenance as an adjunct monitor used alongside other anesthesia monitors. If the NOL value is above 25 for sixty seconds or more, clinicians will evaluate whether more analgesia is needed. If the NOL value is below 25 the patient is considered to have adequately managed nociception.
Time frame: One day
Total opioid requirement during surgery and PACU stay reported in morphine equivalents (mgs)
Time frame: one day
Reduction in time to extubation measured in minutes
Time frame: one day
Reduction in time to PACU discharge readiness measured in minutes
Time frame: one day
Modified Aldrete Score (scale of 0-10)
Time frame: one day
Reduction in PACU pain intensity rating (NRS scale of 0-10 )
Time frame: 1 day
PONV in PACU assessed used accepted PONV symptom scale (0-4)
Time frame: one day
Respiratory depression defined as respiratory rate (RR) below 8 respirations per minute (RPM) for 1 minute. Saturation of less than 90% for 1 minute under continuous monitoring
Time frame: one day
Sedation & Somnolence using Pasero Scale (S 1-4)
Time frame: three days
Patient reported satisfaction levels using standard QoR15 questionnaire responses in the NOL arm only
Time frame: One day
Reduction in hemodynamic instability (hypertensive are MAP above 120mmHg, hypotensive events are MAP below 65mmHg)
Time frame: One day
Use of vasoactive medication (ephedrine, phenylephrine, norepinephrine, atropine) total doses in mgs.
Time frame: three days
Pain intensity. Time points: NRS pain score on a scale of 0-10 , measurement frequency per hospital standard of care.
Time frame: One day
Correlation between time spent with NOL values above 25 (range 0-100 no unit of measurement) and PACU pain intensity ratings measured using the NRS scale (0-10) - to be assessed in the NOL arm only
Time frame: three days
48 hours post-operative opioid consumption measured in morphine equivalents in mgs.
Time frame: three days
Requirement for Acute Pain Service consultation (Y/N)
Time frame: three days
Reduction in rescue opioid requirements - morphine equivalents in mgs
Time frame: three days
Ketamine prescription on the ward (mgs)
Time frame: three days
number of opioid prescriptions and total amount in morphine equivalents (mgs)
Time frame: three days
PONV medication consumption in mgs
Contact information is provided by the study sponsor or research team.
Medasense Biometrics Ltd
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06785350
Agnosia, Nervous System Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT06975072
Neurologic Manifestations, Pain
San Francisco, California, United States
View Trial DetailsNCT04091841
Infections, Neurologic Manifestations
Tehran, Iran
View Trial DetailsNCT03301025
Agnosia, Hemorrhage
Al Mansurah, Dakahlia Governorate, Egypt
View Trial Details